Prothena CorpPRTA
About: Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.
Employees: 163
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
180% more call options, than puts
Call options by funds: $3.5M | Put options by funds: $1.25M
0% more funds holding in top 10
Funds holding in top 10: 3 [Q4 2024] → 3 (+0) [Q1 2025]
2.39% less ownership
Funds ownership: 99.46% [Q4 2024] → 97.07% (-2.39%) [Q1 2025]
6% less funds holding
Funds holding: 169 [Q4 2024] → 159 (-10) [Q1 2025]
13% less capital invested
Capital invested by funds: $741M [Q4 2024] → $647M (-$94.8M) [Q1 2025]
28% less repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 58
32% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 25
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
B of A Securities Tazeen Ahmad | 38%downside $4 | Underperform Downgraded | 28 May 2025 |
Piper Sandler Yasmeen Rahimi | 1,166%upside $81 | Overweight Maintained | 27 May 2025 |
JMP Securities Jason Butler | 353%upside $29 | Market Outperform Maintained | 27 May 2025 |
Chardan Capital Rudy Li | 181%upside $18 | Buy Maintained | 27 May 2025 |
HC Wainwright & Co. Andrew Fein | 119%upside $14 | Buy Maintained | 27 May 2025 |
Financial journalist opinion
Based on 3 articles about PRTA published over the past 30 days
